
Aurora Spine Surpasses 1,500 Successful Surgeries Using DEXA-C™
CARLSBAD, CALIFORNIA, June 16, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation ('Aurora Spine' or the 'Company') (TSXV: ASG) (OTCQB: ASAPF), a leader in innovative spinal implant technology, is proud to announce that its DEXA-C™ system has now been successfully used in more than 1,500 cervical spine procedures across the United States. This milestone underscores the ongoing adoption and trusted performance of the DEXA Technology™ platform, which was honored with the Best Technology in Spine Award.
Aurora's proprietary DEXA Technology™ is the world's first spinal implant platform intentionally engineered to match a patient's bone density across the entire BMD continuum, including normal, osteopenic, and osteoporotic bone. Each implant is designed with an open, porous structure that promotes osseointegration and vascularization, and mimics the lattice architecture of human cancellous bone — resulting in a similar modulus of elasticity and better biomechanical compatibility.
'DEXA-C™ provides surgeons with the first tool that truly puts bone quality at the center of implant selection,' said Trent Northcutt, President and CEO of Aurora Spine. 'With over 1,500 successful surgeries behind us, the data is clear: this technology improves outcomes. And now, we're ready to take it even further as we build out our sales efforts for this platform technology and prepare launch for our second DEXA Technology-enabled product the DEXA-L, which will be rolled out later this year.'
Aurora Spine is excited to announce the upcoming Q4 2025 launch of DEXA-L™, a standalone Anterior Lumbar Interbody Fusion (ALIF) system built on the same award-winning DEXA platform. Like DEXA-C™, the DEXA-L™ implant is designed to address the challenges of spinal fusion in patients with varying bone densities — especially those with osteoporosis.
For decades, spinal implants were primarily developed for patients with healthy bone stock. However, these implants have demonstrated reduced performance in patients with low bone density, where traditional designs may lack sufficient bone-implant contact and fail to achieve long-term fixation. DEXA Technology™ directly addresses this clinical gap, offering a smart, density-matched solution for today's diverse patient population.
Aurora continues its mission to bring personalized spine solutions to market, with a growing DEXA portfolio that includes cervical, lumbar, and sacroiliac fusion systems.
For more information on DEXA Technology™ and Aurora's full product line, visit www.aurora-spine.com.
About Aurora Spine
Aurora Spine is focused on bringing new solutions to the spinal implant market through a series of innovative, minimally invasive, regenerative spinal implant technologies. Additional information can be accessed at www.aurora-spine.com. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurora Spine, including, without limitation, those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Information" in Aurora Spine's final prospectus (collectively, "forward-looking information"). Forward-looking information in this news release includes information concerning the proposed use and success of the company's products in surgical procedures. Aurora Spine cautions investors of Aurora Spine's securities about important factors that could cause Aurora Spine's actual results to differ materially from those projected in any forward-looking statements included in this news release. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ unilaterally from those expressed in such forward-looking statements. No assurance can be given that the expectations set out herein will prove to be correct and, accordingly, prospective investors should not place undue reliance on these forward-looking statements. These statements speak only as of the date of this press release and Aurora Spine does not assume any obligation to update or revise them to reflect new events or circumstances.
Company Contacts: Aurora Spine Corporation
Trent Northcutt
President and Chief Executive Officer
(760) 424-2004
Chad Clouse
Chief Financial Officer
(760) 424-2004
www.aurora-spine.com
Investor Contact:
Adam Lowensteiner
Lytham Partners
(646) 829-9702
Email: asapf@lythampartners.com
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Globe and Mail
32 minutes ago
- Globe and Mail
D-Wave Quantum to Report Second Quarter Fiscal Year 2025 Financial Results on August 7, 2025
D-Wave Quantum Inc. (NYSE: QBTS) ('D-Wave'), a leader in quantum computing systems, software, and services, today announced it will release its financial results for the second quarter of fiscal year 2025 ended June 30, 2025 on Thursday, August 7 before market open. The press release will be available on the D-Wave Investor Relations website: In conjunction with this announcement, D-Wave will host a conference call on Thursday, August 7, 2025, at 8:00 a.m. (Eastern Time), to discuss the Company's financial results and business outlook. The live dial-in number is 1-800-717-1738 (domestic) or 1-646-307-1865 (international). Participants can use those dial-in numbers or can click this link for instant telephone access to the event. The link will be made active 15 minutes prior to the call's scheduled start time. An on-demand webcast will be available on the D-Wave Investor Relations website after the call. Participating in the call will be Chief Executive Officer Dr. Alan Baratz and Chief Financial Officer John Markovich. About D-Wave Quantum Inc. D-Wave is a leader in the development and delivery of quantum computing systems, software, and services. We are the world's first commercial supplier of quantum computers, and the only company building both annealing and gate-model quantum computers. Our mission is to help customers realize the value of quantum, today. Our quantum computers — the world's largest — feature QPUs with sub-second response times and can be deployed on-premises or accessed through our quantum cloud service, which offers 99.9% availability and uptime. More than 100 organizations trust D-Wave with their toughest computational challenges. With over 200 million problems submitted to our quantum systems to date, our customers apply our technology to address use cases spanning optimization, artificial intelligence, research and more. Learn more about realizing the value of quantum computing today and how we're shaping the quantum-driven industrial and societal advancements of tomorrow: Forward-Looking Statements Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading 'Risk Factors' discussed under the caption 'Item 1A. Risk Factors' in Part I of our most recent Annual Report on Form 10-K or any updates discussed under the caption 'Item 1A. Risk Factors' in Part II of our Quarterly Reports on Form 10-Q and in our other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.

National Post
32 minutes ago
- National Post
MindMed to Report Second Quarter 2025 Financial Results on July 31, 2025
Article content NEW YORK — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the 'Company' or 'MindMed'), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will host a live webcast at 4:30 p.m. EDT on Thursday, July 31, 2025 to report financial results for the first quarter ended June 30, 2025, and discuss recent business updates. Article content Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the MindMed website, and archived for at least 30 days after the webcast. Those who plan on participating are advised to join 15 minutes prior to the start time. Article content Article content About MindMed Article content MindMed is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. MindMed trades on NASDAQ under the symbol MNMD. Article content Article content Article content Article content Article content


Globe and Mail
32 minutes ago
- Globe and Mail
MindMed to Report Second Quarter 2025 Financial Results on July 31, 2025
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the 'Company' or 'MindMed'), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will host a live webcast at 4:30 p.m. EDT on Thursday, July 31, 2025 to report financial results for the first quarter ended June 30, 2025, and discuss recent business updates. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the MindMed website, and archived for at least 30 days after the webcast. Those who plan on participating are advised to join 15 minutes prior to the start time. About MindMed MindMed is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. MindMed trades on NASDAQ under the symbol MNMD.